8-K: Safety Shot Secures $16.3 Million Through Direct Offering and Private Placement

Safety Shot, Inc. has successfully priced a registered direct offering and concurrent private placement, raising approximately $16.3 million in gross proceeds to bolster its balance sheet and fund expanded operations.

Summary

• Safety Shot, Inc. completed a registered direct offering and concurrent private placement with accredited investors.
• The registered direct offering involved the sale of 22,993,492 shares of common stock at an offering price of $0.461 per share.
• A concurrent private placement included the issuance of unregistered warrants to purchase up to 45,986,984 shares of common stock.
• These common warrants have a purchase price of $0.125 per warrant and an exercise price of $0.461 per share, are immediately exercisable, and have a five-year term from the date of issuance.
• Total aggregate gross proceeds to the company from both offerings were approximately $16.3 million, before deducting offering expenses.
• The net proceeds are expected to be used for working capital and general corporate purposes.
• Dominari Securities LLC acted as the exclusive placement agent, receiving an 8.0% cash fee of the total gross proceeds from the registered direct offering, a 1.0% non-accountable expense allowance, and $150,000 for legal counsel and other out-of-pocket expenses.
• Dominari Securities LLC also received warrants (Placement Agent Warrants) to purchase up to 1,839,479 shares of common stock at an exercise price of $0.461 per share, with a five-year term.
• The closing of both offerings occurred on July 24, 2025.

Sentiment

Score: 7

Explanation: The filing indicates a successful capital raise that significantly improves the company's financial position and supports strategic growth initiatives, including a recent merger. While there is dilution, the funds are critical for operational expansion and market acceleration. The management's tone is positive and confident regarding the future outlook.

Positives

• Successfully raised approximately $16.3 million in gross proceeds, significantly strengthening the balance sheet.
• Provides critical capital to support daily business activities and expanded operations, especially following the recent shareholder approval of the merger with Yerba.
• Aims to accelerate the commercial footprint and drive long-term value for shareholders.
• The offering includes warrants with a five-year term, providing long-term potential for investors who believe in the company's future growth.

Negatives

• The issuance of a significant number of new shares (22,993,492) and warrants (45,986,984 common warrants plus 1,839,479 placement agent warrants) could lead to substantial dilution for existing shareholders upon exercise.
• The exercise price of $0.461 per share for the warrants is relatively low, potentially indicating a lower valuation or a need to incentivize investors.
• Significant fees and expenses paid to the placement agent (8% cash fee, 1% expense allowance, $150,000 legal fees, plus warrants) will reduce the net proceeds available to the company.
• The company is prohibited from effecting Variable Rate Transactions for six months post-closing, which limits certain future financing flexibility.

Risks

• Dilution Risk: The issuance of new shares and a large number of warrants could dilute the ownership percentage and per-share value for existing shareholders.
• Market Price Volatility: Future open market or derivative transactions by purchasers, including short sales, may negatively impact the market price of the company's publicly-traded securities.
• Regulatory Compliance: Failure to maintain compliance with SEC filing requirements (e.g., Rule 144(c)(1) public information) could result in liquidated damages.
• Registration Statement Effectiveness: The company is obligated to file and ensure the effectiveness of a registration statement for the resale of warrant shares, with potential penalties if deadlines are missed.
• Operational Risks: The success of the financing depends on the company's ability to effectively execute a seamless integration with Yerba and accelerate its commercial footprint, which carries inherent operational and execution risks.

Future Outlook

The company expects to use the net proceeds from the offering for working capital and general corporate purposes. This capital is intended to support the daily business activities of its expanded operations, facilitate a seamless integration following the merger with Yerba, and accelerate its commercial footprint to drive long-term value for shareholders.

Management Comments

• "This financing is a critical step that comes at a pivotal time for our company, following the recent shareholder approval of our merger with Yerba."
• "It significantly strengthens our balance sheet and provides us with the capital to support the daily business activities of our expanded operations, execute a seamless integration, and accelerate our commercial footprint."
• "We appreciate the confidence shown by our new institutional partner and are now better positioned than ever to drive long-term value for our shareholders."

Industry Context

Safety Shot, Inc. operates in the wellness and dietary supplement industry. This capital raise, occurring after shareholder approval of a merger with Yerba, suggests a strategic move towards expansion and integration within this sector. The funds are earmarked for operational scaling and commercial footprint acceleration, indicating a focus on market penetration and growth in a competitive industry.

Comparison to Industry Standards

• The offering structure, combining a registered direct offering with a concurrent private placement of warrants, is a common method for publicly traded companies, particularly smaller cap firms, to raise capital efficiently from institutional investors without a full public underwritten offering.
• The placement agent fees (8% cash fee, 1% expense allowance, plus warrants) are within the typical range for such transactions, which can vary from 5% to 10% for cash fees, often with additional warrant coverage, depending on the size and risk profile of the offering.
• The exercise price of $0.461 per share for the warrants, matching the offering price, is standard for warrants issued in conjunction with direct offerings, aiming to provide upside participation to investors.
• The five-year term for the warrants is a common duration, offering investors a reasonable timeframe to exercise.
• The beneficial ownership limitation (4.99% or 9.99%) is a standard provision to prevent investors from triggering beneficial ownership reporting requirements (e.g., Schedule 13D) or takeover provisions without prior notice or company approval.

Stakeholder Impact

• Shareholders: Will experience dilution due to the issuance of new shares and warrants. However, the capital raise strengthens the company's financial position, potentially supporting future growth and long-term value.
• Employees: The capital infusion supports expanded operations and business activities, which could lead to job stability or growth opportunities.
• Customers: Funds are intended to accelerate commercial footprint, potentially leading to wider product availability and improved services.
• Creditors: A strengthened balance sheet and improved working capital position reduce financial risk, benefiting creditors.

Next Steps

• Use net proceeds for working capital and general corporate purposes.
• Execute a seamless integration following the merger with Yerba.
• Accelerate commercial footprint.
• File a registration statement on Form S-1 for the resale of Common Warrant Shares within 10 calendar days of the Securities Purchase Agreement date.
• Cause the S-1 registration statement to become effective within 45 days (or 75 days if a full review by the SEC occurs) following the closing date.
• Maintain the listing or quotation of the Common Stock on its Trading Market and apply to list all newly issued shares and warrant shares.
• Potentially engage Dominari Securities LLC for future financial advisory or capital-raising activities for 18 months post-closing.

Key Dates

Recommendation

The capital raise provides essential funding for Safety Shot's operations and strategic integration following its merger, which is a positive development for the company's stability and growth prospects. However, the significant dilution from the issuance of new shares and warrants, coupled with the relatively low offering price, could put near-term pressure on the stock. Investors should hold to observe how the company effectively deploys the capital to achieve its stated goals of seamless integration and commercial acceleration, and how it manages the potential for further dilution from warrant exercises. The long-term value creation hinges on successful execution of the post-merger strategy.

Keywords

Safety Shot, SHOT, Registered Direct Offering, Private Placement, Common Stock, Warrants, Capital Raise, Equity Financing, SEC Filing, Form 8-K, Wellness, Dietary Supplement, Yerba, Nasdaq, Dilution, Investment, Corporate Finance